Characterization of MALS/Velis-1, -2, and -3: a Family of Mammalian LIN-7 Homologs Enriched at Brain Synapses in Association with the Postsynaptic Density-95/NMDA Receptor Postsynaptic Complex

Kiwon Jo,1 Rachel Derin,2 Min Li,2 and David S. Bredt1

1Department of Physiology, School of Medicine, University of California at San Francisco, San Francisco, California 94143-0444, and 2Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Protein assembly at the postsynaptic density (PSD) of neuronal synapses is mediated in part by protein interactions with PSD-95/disc large/zona occludens-1 (PDZ) motifs. Here, we identify MALS-1, -2, -3, a family of small synaptic proteins containing little more than a single PDZ domain. MALS-1, -2, and -3 are mammalian homologs LIN-7, a Caenorhabditis elegans protein essential for vulval development. In contrast to functions for LIN-7 in epithelial cells, MALS-1 and -2 are selectively expressed in specific neuronal populations in brain and are enriched in PSD fractions. In cultured hippocampal neurons, MALS proteins are clustered together with PSD-95 and NMDA type glutamate receptors, consistent with a postsynaptic localization for MALS proteins. Immunoprecipitation and affinity chromatography studies readily identify association of MALS with PSD-95 and an NMDA receptor subunit. The PDZ domain of MALS selectively binds to peptides terminating in E-T/S-R/X-V/I/L, which corresponds to the C terminus of NMDA type 2 receptors and numerous other ion channels at the PSD. This work suggests a role for MALS proteins in regulating recruitment of neurotransmitter receptors to the PSD.

Key words: MALS; PDZ; LIN-7; PSD-95; NMDA receptor; postsynaptic density; C. elegans

Rapid and reliable synaptic transmission requires that neurotransmitter receptors and associated downstream signaling molecules are clustered together beneath the postsynaptic membrane (Sheng, 1996; Kornau et al., 1997; Craven and Bredt, 1998). Mechanisms for organizing postsynaptic signal transduction cascades at excitatory synapses in brain are not yet clear. Valuable clues have come from studies of the postsynaptic density (PSD), an electron-dense cytoskeletal structure enriched with neurotransmitter receptors and associated transduction machinery (Cho et al., 1992). Assembly of some components of the PSD appears to be mediated by PSD-95/synapse-associated protein-90 (SAP-90) and related membrane-associated guanylate kinase (MAGUK) proteins (Kistner et al., 1993; Sheng, 1996; Kornau et al., 1997; Craven and Bredt, 1998). PSD-95 is anchored to synaptic membranes by N-terminal palmitoylation (Topinka and Bredt, 1998) and contains three PSD-95/discs large/zona occludens-1 (PDZ) protein–protein interaction motifs that directly bind to NMDA type glutamate receptors (Kornau et al., 1995) and to certain downstream signaling enzymes, including neuronal nitric oxide synthase (nNOS) (Brenman et al., 1996; Craven and Bredt, 1998).

PDZ domains are protein interaction domains that often bind to the very C terminus of protein targets (Doye et al., 1996; Songyang et al., 1997). This binding is primarily determined by the final four amino acids of the protein target; however, upstream sequences in the target are also critically involved. Evidence that PDZ proteins mediate receptor localization at synapses and other cell–cell junctions derives from studies of invertebrates. Mutation of Discs-Large tumor suppressor protein, a Drosophila MAGUK related to PSD-95 (Woods and Bryant, 1991), causes abnormalities of synaptic structure (Lahey et al., 1994), including disruption of Shaker K+ channel clustering at the larval neuromuscular junction (Tejedor et al., 1997). In Caenorhabditis elegans, studies of vulval development have implicated several PDZ proteins in polarized receptor localization to the basolateral membrane of vulval precursor cells. In this pathway, three PDZ-containing proteins mediate basolateral localization of LET-23, a receptor tyrosine kinase essential for vulval development (Simske et al., 1996). The three PDZ proteins are LIN-2, a MAGUK protein similar to mammalian CASK (Hata et al., 1996; Hoskins et al., 1996); LIN-10, a protein containing two PDZ domains similar to mammalian Mint/X11 (Okamoto and Sudhof, 1997; Kaeck et al., 1998); and LIN-7, a small protein containing little more than a single PDZ domain (Simske et al., 1996). Molecular mechanisms by which LIN-2, LIN-7, and LIN-10 anchor LET-23 are uncertain, but LIN-7 directly binds LET-23 and associates with it along the basolateral membrane of vulval precursor cells (Simske et al., 1996).

Because synaptic junctions bear certain similarities with epithelial tight junctions (Cho et al., 1992), we wondered whether mammalian homologs of LIN-7 might exist and play a role in synaptic function. Here, we identify MALS-1, -2, -3 (for mammalian LIN-seven protein), which are identical to the Velis that were
reported (Butz et al., 1998) while this work was under review. MALS are homologous to *C. elegans* LIN-7 (Simske et al., 1996), and each contains little more than a single PDZ domain. MALS-1 and -2 are neuron specific, whereas MALS-3 is also expressed in peripheral tissues. MALS-1 and -2 are highly enriched in postsynaptic density preparations in association with PSD-95/NMDA receptor complexes. Affinity panning indicates that the PDZ domain of MALS-2 preferentially binds peptides terminating E-T/S-R/X-I/V/L, which resembles the C terminus of type 2 NMDA receptors. These results suggest a possible role for MALS proteins in regulating receptor clustering associated with the PSD-95 protein complex.

**MATERIALS AND METHODS**

**Northern blotting.** Multiple tissue rat Northern blots (RB no. 1002) were purchased from Origene (Rockville, MD). Blots were hybridized with random primed \(^{32}P\)-labeled probes (10\(^7\) cpmp/\(\mu\)g), which were generated using the 3' UTR of MALS cDNAs as templates. Hybridizations were done in Express-Hyb buffer at 68°C for 1 hr as specified by the manufacturer (Clontech, Palo Alto, CA). After hybridization, blots were washed twice at room temperature for 20 min at low stringency (2 \(\times\) SSC and 0.1% SDS) and twice at 50°C for 20 min at high stringency (0.1 \(\times\) SSC and 0.1% SDS). The blots were exposed overnight to x-ray film at \(-80°C\).

**DNA constructs.** Glutathione-S-transferase (GST) fusion constructs were prepared by PCR into pGEX4T vector (Pharmacia Biotech, Uppsala, Sweden) and confirmed by sequencing. The following fusion pro-
proteins were constructed: GST:MALS-1(N81), residues 1–81; GST:
MALS-2(N70), residues 1–70; GST:MALS-2(total), residues 1–207;
GST:MALS-2(PDZ), residues 92–207; GST:MALS-2(19–207), residues
19–207; GST:NR2B(C9), C-terminal nine amino acids. For expression in
COS7 cells, the full-length coding regions of MALS-1, -2, and -3 were
subcloned into mammalian expression vector pcDNA3 (Invitrogen,
Carlsbad, CA), NMDA receptor subunit 2B (NR2B) into pRK5 (Ge-
nentech, San Francisco, CA), PSD-95 into pGW1-CMV (British Bio-
tech, Oxford, UK), and MALS-2 into pEGFP-c2 (Clontech).

Antisera. GST:MALS-2(19–207) and GST:MALS-1(1–81) were ex-
pressed and purified from *Escherichia coli* as described previously (Bren-
man et al., 1996). Rabbits were immunized with the MALS-2 fusion
protein, and guinea pigs were immunized with the MALS-1 fusion
protein. Antigens were emulsified in complete and incomplete Freund’s
adjuvant. Serum bleeds were evaluated by ELISA. For affinity purifica-
tion of MALS-2 antibody, MALS-2 antisera was precipitated with
40% ammonium sulfate, resuspended with 500 mM Tris-HCl, pH 7.5,
dialyzed in 10 mM Tris-HCl, pH 7.5, and applied to a column of GST
protein conjugated to Affigel-10 (Bio-Rad, Hercules, CA). The flow-
through was collected and reapplied to a column of GST:MALS-2 fusion
protein immobilized to Affigel-10. The column was washed with 20 vol of
buffer containing 10 mM Tris-HCl, pH 7.5, and 500 mM NaCl. The
MALS-2 antibody was eluted with 1 bed volume of 100 mM glycine, pH
2.5. Antibodies to Kv1.4 (a gift from Lily Jan), PSD-95 (Affinity BioRe-
agents, Golden, CO), erbB4 (NeoMarkers, Fremont, CA), synaptophysin
(Sigma, St. Louis, MO), NR2B (Transduction Labs, Lexington, KY),
GST (Santa Cruz Biotechnology, Santa Cruz, CA), neurofilament-H
(Zymed, San Francisco, CA), and NR1 (PharMingen, San Diego, CA) were
used as specified by the supplier.

Western blot analysis and immunohistochemistry. For Western blotting,
tissues were homogenized in 20 vol (w/v) of TEE (25 mM Tris-HCl, pH
7.5, 1 mM EDTA, and 1 mM EGTA) containing 1 mM phenylmethylsul-
forylfluoride (PMSF). Proteins were separated by 10% SDS-PAGE, and gels were transferred to polyvinylidene difluoride (Millipore, Bedford, MA) membranes, which were blocked with 3% BSA. Western blots were developed using enhanced chemiluminescence as described previously (Brenman et al., 1996). Protein concentration was determined by Bradford assay (Bio-Rad). For immunohistochemistry, rats were perfused with 4% freshly depolymerized paraformaldehyde in 0.1M phosphate buffer. Brains were removed and cryoprotected overnight in 20% sucrose, and free-floating sections (40 μm) were cut on a sliding microtome. Immunohistochemical staining used an avidin–biotin–peroxidase system (ABC Elite; Vector Laboratories, Burlingame, CA) according to the manufacturer’s instructions. Peroxidase staining was developed using 3,3′-diaminobenzidine as the chromogen.

**Subcellular fractionation.** Subcellular fractions of rat cerebral cortex were prepared by differential centrifugation as described previously (Li et al., 1996). Rat cerebral cortices were homogenized in buffer containing 320 mM sucrose and 4 mM HEPES-NaOH, pH 7.3. The homogenate was centrifuged for 10 min at 1000 g to produce a pellet (P1, crude nuclear fraction). The supernatant (S1) was centrifuged at 12,000 g for 15 min to produce a pellet (P2) and supernatant (S2). The pellet was resuspended in the original volume of homogenization buffer and centrifuged for 15 min at 13,000 g to yield the crude synaptosomal fraction (P2'). The P2' fraction was resuspended in homogenization buffer and hypotonically lysed by addition of 9 vol of ice-cold water and homogenized in a glass Teflon homogenizer (three strokes). The lysate was brought to 260,000 g for 2 hr to give a crude synaptosomal vesicle pellet (LP2) and a cytosolic synaptosomal supernatant (LS2). In a separate procedure, synaptosomes and PSD fractions were prepared from five rat cerebral cortices as described previously (Cho et al., 1992). Briefly, the synaptosome fraction purified by discontinuous sucrose density gradient centrifugation was extracted once or twice with ice-cold 0.5% Triton X-100 and then centrifuged to obtain the PSD (one Triton) and PSD (two Triton) pellets. The PSD (one Triton) pellet was separately extracted with 3% Sarcosyl and centrifuged to obtain the PSD (one Triton + Sarcosyl) pellet.

**Transfection of COS7 cells.** COS7 cells were grown in DMEM containing 10% fetal bovine serum, penicillin, streptomycin, and l-glutamine in 5% CO2. Cells were transiently transfected with CDNA constructs of full-length PSD-95, NR2B, and MALS proteins in mammalian expression vectors using Lipofectamine reagent according to the manufacturer’s protocol (Life Technologies, Gaithersburg, MD).

**Immunoprecipitation.** Rat cerebral cortices were homogenized in 20 vol (w/v) of deoxycholate (DOC) buffer (containing 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 2 mM β-mercaptoethanol, 50 mM NaF, 1 mM sodium vanadate, and 20 mM ZnCl2) and centrifuged at 100,000 g for 30 min to yield a membrane fraction. The membranes were resuspended in DOC buffer supplemented with 1% sodium deoxycholate and solubilized for 2 hr at 4°C. Triton X-100 was added to 1%, and the preparation was cleared by centrifugation at 100,000 g for 30 min. Affinity-purified antibody (5 μg) was added to 1 ml of solubilized membrane extract (500 μg/ml). After a 60 min incubation on ice, 50 μl of protein A Sepharose (1:1 slurry in TEE buffer) was added to precipitate antibodies. The protein A pellet was washed three times with TEE buffer containing 1% Triton X-100 and 150
mM NaCl. Immunoprecipitated proteins were denatured with loading buffer and resolved by 10% SDS-PAGE.

**GST fusion protein affinity chromatography.** GST fusion proteins were expressed in *Escherichia coli* and purified on glutathione Sepharose beads as described previously (Brenman et al., 1995). For “pull-down” assay, transfected COS7 cells or dissected cerebral cortices were homogenized in 20 vol (w/v) of DOC buffer and solubilized as described above. Solubilized membranes were incubated with control (GST) or GST fusion protein beads for 1 hr. Samples were loaded into disposable columns, which were washed with 50 vol of buffer containing 1% Triton X-100 and 150 mM NaCl and protein eluted with loading buffer.

**Neuronal cell culture and immunocytochemistry.** Cultures of embryonic day 18 (E18) rat hippocampal neurons were grown as described previously (Apperson et al., 1996). After 14 d in culture, the neurons were fixed and stained with affinity-purified antibodies as described previously (Apperson et al., 1996).

**Affinity panning.** A fusion protein GST:MALS-2(19–207) was used for affinity panning of a random LacI-based peptide library. The procedures for PDZ domain panning and ELISA detection have been described previously in detail (Stricker et al., 1997). Briefly, a pool of oligonucleotides encoding 15 random amino acids was cloned in frame C terminal to LacI coding sequences. The recombinant LacI binds to lac O sites present on the same plasmid yielding LacI-plasmid complexes that were purified from *E. coli*. Affinity panning selects peptides that interact with target GST:MALS-2. The bound plasmid DNAs were specifically separated from the LacI proteins by addition of isopropyl-β-D-thiogalactopyranoside. The recovered plasmids were retransformed, amplified, and used for subsequent rounds of

**Figure 5.** MALS protein expression progressively increases during brain development. Homogenates from rat brain at various developmental stages (15 μg/lane) were immunoblotted with the affinity-purified MALS antibody. Embryonic (E) and postnatal (P) days are indicated.

**Figure 6.** MALS proteins are enriched in PSD fractions. A. Subcellular fractions of rat cerebral cortex were prepared by differential centrifugation. Aliquots from this fractionation were probed by Western blotting with MALS antibody. Antibodies against PSD-95 and NR2B, synaptophysin and neurofilament-H, were used as controls for postsynaptic proteins, a synaptic vesicle protein and a nonsynaptic protein, respectively. Fractions (5 μg/lane, except 25 μg/lane for homogenates) are marked: H, Homogenates; P1, a crude nuclear fraction; S1, a supernatant; P2, a crude membrane fraction; P2’, a crude synaptosomal fraction; LP1, a heavy membrane fraction; LP2, a synaptic vesicle fraction; LS2, a cytosolic synaptosomal fraction. B. MALS proteins are enriched in the PSD fraction. Rat cerebral cortex homogenate and synaptosomes and isolated PSDs extracted once with 0.5% Triton X-100 (one triton), twice with 0.5% Triton X-100 (two triton), or once with 0.5% Triton X-100 followed by 3% Sarcosyl (one triton + sarcosyl) were analyzed by immunoblotting with the affinity-purified MALS antibody. Antibodies against PSD-95, NR2B and Kv1.4, and synaptophysin were used as controls for postsynaptic and presynaptic membrane proteins, respectively.
panning. After three rounds of panning, plasmids encoding PDZ domain interacting peptides were sequenced.

RESULTS
To identify possible mammalian homologs of LIN-7, we searched the Expressed Sequence Tag database and identified three candidates, MALS-1, -2, and -3 (accession numbers AA405216 from human, W75523 from mouse, and AA462021 from mouse, respectively), that show high homology with the C-terminal two thirds of LIN-7, including the PDZ domain. Sequencing of these cDNAs demonstrated that they encode proteins that share ~70% identity with each other and LIN-7 (Fig. 1). Particularly high homology is found in the PDZ domains, which are 80–90% identical between MALS-1, -2, and -3. MALS-1 encodes a protein of 233 amino acids (predicted molecular weight, 26 kDa), MALS-2 a protein of 207 amino acids (23 kDa), and MALS-3 a protein of 197 amino acids (22 kDa). The only major difference between the MALS and LIN-7 is that LIN-7 contains an N-terminal extension of ~100 amino acids that is not present in the MALS.

To determine whether the MALS are potentially expressed in neurons, we performed Northern blotting on poly(A+) RNA purified from a variety of rat tissues. We used unique [32P]-labeled cDNA probes from the 3'UTR for MALS-1, -2, and -3 to avoid possible cross-hybridization. We found that each probe recognizes unique bands in poly(A+) RNA samples from brain (Fig. 2). MALS-1 specifically hybridizes to a band of 1.3 kb, whereas MALS-2 primarily recognizes a band of 0.8 kb and also to a weaker band at 2.0 kb, and MALS-3 to a band of 4.4 kb. Strikingly, we found that expression of both MALS-1 and MALS-2 is brain-specific. MALS-1 and -2 hybridizing bands are not detectable, even with long exposure, in RNA from heart, kidney, spleen, thymus, or liver. On the other hand, MALS-3 mRNA is most abundantly expressed in kidney, followed by brain and liver, and very faint bands are seen in thymus and heart.

For analysis of MALS protein expression, we developed an affinity-purified antibody to full-length MALS-2 (see Materials and Methods). Because the PDZ domain is 80–90% identical between MALS-1, -2, and -3, we expected this antibody to react with all three proteins. Western blotting of total brain extracts revealed that the antibody specifically reacts with protein bands of 30 and 25 kDa, which closely correspond to the predicted sizes of MALS-1 and MALS-2 and -3, respectively (Fig. 3A). The top 30 kDa band is almost equally distributed in membrane and soluble fractions of rat brain, and the bottom 25 kDa band is primarily associated with membranes. Because the open reading frames of MALS-1, -2, and -3 are smaller than LIN-7, we considered the possibility that the cDNAs we were analyzing may not be full length. To evaluate this, we cloned the MALS-1, -2, and -3 cDNAs into a mammalian expression vector (pcDNA3), and expressed them in COS7 cells. Western blotting demonstrates the antibody raised to full-length MALS-2 (designated simply as MALS antibody) recognizes all three MALS proteins. MALS-2 and -3 expressed in transfected cells migrate at 25 kDa and are indistinguishable from the bottom 25 kDa band detected in brain homogenates (Fig. 3A). MALS-1 expressed in COS7 cells migrates at 30 kDa, corresponding to the top band in brain extracts. MALS proteins are not detected in untransfected COS7 cells. To determine whether the top 30 kDa band detected in brain homogenates
corresponds to MALS-1, we developed an antiserum against the relatively unique N-terminal 81 amino acids of MALS-1 (see Materials and Methods). In crude brain extracts, this antibody recognizes a band of 30 kDa and a set of presumably nonspecific bands at 75–80 kDa (Fig. 3B). Immunoprecipitation with the affinity-purified MALS antibody followed by Western blotting with the MALS-1 antibody confirmed that the 30 kDa band corresponds to MALS-1 and that the slower migrating bands are likely to be nonspecific. The predicted molecular masses of MALS-2 and MALS-3 are similar (22 and 23 kDa, respectively), suggesting that the bottom band seen in Western blots is likely to contain both MALS-2 and MALS-3.

Western blotting on a variety of tissues confirmed that MALS are expressed at greatest levels in brain (Fig. 4A). In kidney, we detect an intense band of 25 kDa, which is explained by the high levels of MALS-3 mRNA that are detected in kidney by Northern blotting (Fig. 2). MALS proteins are not readily detectable in spleen, thymus, liver, lung, skeletal muscle, or pancreas. In heart extracts, we detect low levels of both the 25 and 30 kDa bands (Fig. 4A). These protein bands detected by Western blotting in heart may reflect MALS-3 but may also reflect related MALS proteins that have not been molecularly cloned here.

Western blotting indicated that MALS proteins are ubiquitously expressed in brain and localized in cerebral cortex, cerebellum, hippocampus, olfactory bulb, corpus striatum, and medulla. MALS proteins were not detectable in spinal cord (Fig. 4B). The spatial distribution of MALS protein in brain was further evaluated by immunohistochemical staining. Figure 4C represents a dark-field image of a sagittal brain section labeled with MALS antibody. MALS is discretely localized in specific brain regions (data not shown). Consistent with Western blotting, MALS protein is found most prominently in cerebellum, cerebral cortex, hippocampus, corpus striatum, and thalamus (Fig. 4C).

To determine whether MALS proteins are likely to be involved primarily in developmental processes, or alternatively if they may also have roles in mature brain, we evaluated expression by Western blotting throughout rat ontogeny. We detected only low levels of the 25 kDa band (MALS-2 and -3) in extracts from E13; the intensity of this 25 kDa band (MALS-2 and -3) in extracts from E13; the intensity of this 25 kDa band progressively increases during development and reaches maximal levels in the adult. Expression of the 30 kDa band (MALS-1) is not robustly detectable until the second postnatal week, and expression progressively increases thereafter (Fig. 5).

Biochemical fractionation followed by Western blotting was next performed to determine the subcellular localization of the MALS proteins. We found that the MALS were all enriched in a heavy membrane fraction (LP1), and only very low levels of MALS-2 and -3 were found in the synaptic vesicle fraction (LP2). This distribu-
that MALS may be localized at synapses (Fig. 7). To evaluate this, we double-labeled cultures for MALS and PSD-95 or NR1. Previous characterization of these cultures demonstrates that punctate dendritic labeling for PSD-95 and NR1 occurs at synapses as the puncta colocalize with synaptophysin (Torres et al., 1998). We found that most of the punctate dendritic clusters of MALS immunofluorescence were colocalized with NR1 and PSD-95 along the neuronal processes at putative synaptic sites (Fig. 7A,B).

Because MALS proteins copurify with PSD-95 in brain fractions and are colocalted with PSD-95 at synapses, we asked whether these proteins occur together in a protein complex. To determine whether MALS associate with PSD-95, we performed immunoprecipitation analysis (Fig. 8A). We found that our antibody to MALS readily immunoprecipitates PSD-95 and NR2B from solubilized membranes of rat cerebral cortex. In contrast, CaM kinase II α subunit, which is also enriched in PSD, does not coimmunoprecipitated with MALS. Controls with the preimmune MALS antiserum or MALS-antiserum that was presorbed with immunogen block the coimmunoprecipitation, confirming the selectivity of the association. In brain extracts that were initially boiled in 0.5% SDS, MALS are still immunoprecipitated, although PSD-95/NR2B are not, indicating that coprecipitation requires native protein interactions (Fig. 8A). Because the MALS antibody cross-reacts with all three MALS proteins, it was not clear which protein(s) are associate with the PSD-95/NMDA receptor complexes. To address this question, we probed PSD-95 immunoprecipitates for the presence of MALS proteins. Both the 25 and 30 kDa bands are detected in the PSD-95 immunoprecipitates, suggesting that multiple MALS proteins associate with PSD-95/NMDA receptor complexes. To evaluate these interactions in a different way, we performed affinity chromatography or pull-down assays using a fusion protein of MALS-2 linked to GST. Solubilized cerebrocortical membranes were incubated with either GST:MALS-2 or GST alone immobilized to glutathione–Sepharose beads. After this binding reaction, columns were washed extensively, and retained proteins were eluted with SDS. Western blotting indicated that PSD-95 and NR2B are selectively retained by the GST:MALS-2 beads (Fig. 8C).

These associations detected among proteins from brain extracts suggested a possible direct interaction of MALS with either NR2B or PSD-95. To address this, we investigated binding of MALS-2 to PSD-95 or NR2B expressed in transfected COS7 cells, which do not otherwise express PSD-95 or NR2B. We first performed pull-down assays with GST:MALS-2 on extracts from cells individually transfected with either PSD-95 or NR2B. We found that the GST:MALS-2 fusion does not directly bind to PSD-95 but does bind to NR2B. We performed similar pull-down assays on extracts from cells cotransfected with PSD-95 and NR2B. From these cotransfections, we found that both PSD-95 and NR2B avidly bind to the MALS-2 fusion protein column, suggesting formation of a tight ternary complex (Fig. 8D).

The direct binding of MALS to NR2B, which terminates in E-S-D-V, is reminiscent of PDZ domain interactions. To define the regions of MALS and NR2B that are involved in the interaction, we prepared GST fusion proteins representing isolated regions of MALS-2 and NR2B. A GST fusion containing only the PDZ domain of MALS-2 [GST:MALS-2(PDZ)] binds NR2B expressed in COS7 cells, whereas an MALS-2 construct containing only the unique N-terminal region [GST:MALS-2(N70)] is inactive (Fig. 9A). Also, a GST fusion containing only

---

Figure 9. MALS binds to NR2B through a typical PDZ domain/C-terminal tail interaction. A. Solubilized extracts from COS7 cells transfected with NR2B (lane 1) were pulled-down with GST alone (lane 2), GST:MALS-2(N70) (lane 3), GST:MALS-2(PDZ) (lane 3) or GST: MALS-2(total) (lane 4). Retained proteins were analyzed by immunoblotting. B. Cell homogenates from COS7 cells transfected with GFP: MALS-2 (lane 1) were pulled-down with GST alone (lane 2) or with GST:NR2B(C9) (lanes 3–7). A peptide corresponding to the C-terminal nine amino acids of NR2B (ESDV) was added to the binding reaction at 5 (lane 4) or 50 (lane 5) μM. A similar peptide in which the last four amino acids were replaced with EADA was added into the binding reaction at 5 (lane 6) or 50 (lane 7) μM. Retained GFP:MALS-2 was detected by immunoblotting with a GFP antibody.
the C-terminal nine amino acids of NR2B [GST:NR2B(C9)] binds to a GFP:MALS-2 protein expressed in COS7 cells. Binding of MALS-2 to the C terminus of NR2B is potently blocked by a peptide corresponding to the final nine amino acids of NR2B. This effect is specific because a control 9-mer peptide in which the critical serine and valine are mutated to alanine does not disrupt the interaction (Fig. 9B).

To evaluate binding properties for the PDZ domain of MALS, we took advantage of a peptide display strategy and screened billions of distinct peptides to select sequences that specifically bind to the PDZ domain of MALS-2. We have previously used this in vitro selection strategy to determine optimal peptides for binding to PDZ domains of nNOS and PSD-95 (Stricker et al., 1997). For this technique, a GST fusion protein of full-length MALS-2 was incubated with a 15-mer Lacl library of complexity $1.3 \times 10^{10}$. After three rounds of panning, the binding specificity of the isolated clones was determined by ELISA. The sequences of 21 interacting peptides were determined (Table 1). The preferred C-terminal peptide for interaction with MALS-2 is E-T/S-R/X-V/I/L, which matches the C terminus of NR2B. Overall, this selectivity is similar to that seen for PDZ domains for PSD-95, which best interact with proteins terminating E-T/S-X-V/I (Songyang et al., 1997; Stricker et al., 1997). The differences are that MALS-2 tolerates leucine and phenylalanine at the 0 position and that MALS-2 has a significant preference for differences are that MALS-2 tolerates leucine and phenylalanine.

### Table 1. Sequence alignment of MALS binding peptides

<table>
<thead>
<tr>
<th>Clone no.</th>
<th>Sequence</th>
<th>Clone no.</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>W-1</td>
<td>GGGVSRIGFGCGRRCYRL</td>
<td>W-11</td>
<td>GGGVFEEVYAFESLETAL</td>
</tr>
<tr>
<td>W-2</td>
<td>**********GGGVHETRV</td>
<td>W-12</td>
<td>GGGVRMPLGFEQLETRV</td>
</tr>
<tr>
<td>W-3</td>
<td>**********GGGELWAETS</td>
<td>W-13</td>
<td>GGGTRRGGEWRSFRVESRL</td>
</tr>
<tr>
<td>W-4</td>
<td>GGGLAGGWNLKRHTRGLV</td>
<td>W-14</td>
<td>GGGCGRSQSVRAGAESRV</td>
</tr>
<tr>
<td>W-5</td>
<td>**********GGGTLLGRET5V</td>
<td>W-15</td>
<td>GGGAWNREPEGWNETRI</td>
</tr>
<tr>
<td>W-6</td>
<td>GGGLHMRYGIOGYRTGVG</td>
<td>W-16</td>
<td>GGGRLSIRDYVRSGETAL</td>
</tr>
<tr>
<td>W-7</td>
<td>**********GGGAWEWMSYI</td>
<td>W-17</td>
<td>GGGRRSLSGDEAWETRV</td>
</tr>
<tr>
<td>W-8</td>
<td>GGGSRVOADWSFETRF</td>
<td>W-18</td>
<td>GGGNHSASEYVMTRESOL</td>
</tr>
<tr>
<td>W-9</td>
<td>GGGTWQEHGGGICMGETSL</td>
<td>W-19</td>
<td>GGGMNSESAAVCLRETGV</td>
</tr>
<tr>
<td>W-10</td>
<td>**********GGGMRETTTL</td>
<td>W-20</td>
<td>**********GGGMMETSV</td>
</tr>
<tr>
<td></td>
<td>W-21 **GGYESAWAGLTESRV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sequence alignment of 21 independent MALS binding peptides. The deduced amino acid sequences of 21 independent clones were obtained and aligned according to the first stop codon. The library template is GGG-XXXXXXXXXXXXXXXXXX.

**DISCUSSION**

The primary finding of this study is the identification of MALS-1, -2, and -3, a family of mammalian homologs of *C. elegans* LIN-7 that are enriched at the postsynaptic density of central synapses. Similar to LIN-7 in *C. elegans*, the MALS are small proteins that each contain a C-terminal PDZ domain and a short N-terminal sequence (Simske et al., 1996). The amino acid sequences of this family of proteins are remarkably conserved between mammals and nematodes (65–70% identical) and suggest the functional roles for these proteins are similar. In *C. elegans*, however, LIN-7 occurs in epithelial cells rather than in neurons, and LIN-7 mutants have a vulvalas phenotype rather than a neuronal phenotype (Simske et al., 1996). In vulval precursor epithelial cells, LIN-7 localizes a receptor tyrosine kinase receptor to the basolateral cell junction (Simske et al., 1996). By analogy, we suspect that the MALS binds to neurotransmitter receptors in brain and targets them to the PSD. Indeed, we find that the PDZ domain of MALS can bind the C terminus of NR2B and that MALS occur together with this glutamate receptor in the PSD.

The synaptic localization of MALS-1, -2, and -3 in neurons compared with the basolateral localization of LIN-7 in *C. elegans* epithelial vulval precursor cells is consistent with studies that have identified structural analogies between epithelial tight junctions and neuronal synapses (Choo et al., 1992; Bredt, 1998). For example, high levels of the PSD-95/SAP-90 family of MAGUK proteins at neuronal synapses (Choo et al., 1992; Kistner et al., 1993; Lahey et al., 1994; Guan et al., 1996) is paralleled by ubiquitous expression of related MAGUKs, such as zona occludens-1, -2, and -3, at epithelial tight junctions (Woods and Bryant, 1991; Willott et al., 1993; Jesaitis and Goodenough, 1994). In addition to these structural similarities, neurons and epithelial cells share certain common mechanisms for subcellular sorting of membrane proteins. Seminal studies by Dotti and Simons (1990) have shown that some (but not all) proteins that occur at the basolateral domain of epithelial cells are targeted to neuronal dendrites. Furthermore, the same cytosolic sequences that determine basolateral localization of epithelial membrane proteins can mediate dendritic sorting of certain neuronal proteins (Jareb and Banker, 1998). Because LIN-7 plays a primary role in localizing LET-23, a transmembrane receptor to the basolateral membrane of vulval precursors (Simske et al., 1996), we suspect that MALS proteins may contribute to dendritic and postsynaptic targeting of neuronal receptors. In support of this notion, a very recent study showed that *lin-10* is essential for postsynaptic targeting of a glutamate receptor in *C. elegans* interneurons (Rongo et al., 1998). Although *lin-7* was specifically not required for postsynaptic targeting of the glutamate receptor (Rongo et al., 1998), it is possible that a LIN-7 isoform in *C. elegans* neurons cooperates with *lin-10* to mediate receptor sorting.

To help identify proteins that might be synaptically targeted by MALS, we determined the binding specificity of the PDZ domain. This analysis demonstrated that the PDZ domain of MALS-2 has a binding preference for polypeptides terminating in E-T/S-R/X-V/I/L, which matches the C terminus of NR2B. This generally conforms to the Phe consensus for PDZ domains (Songyang et al., 1997). Interestingly, this generally matches the C terminus of LET-23 (Q-T-C-L) and is consistent with the ob-
served interaction between LIN-7 and LET-23 (Hoskins et al., 1996; Kaech et al., 1998). Our searches of the database indicated that erbB4, but not other epidermal growth factor receptor tyrosine kinases, terminates with a sequence (N-T-T-V) that might bind the MALS. To detect possible interaction, we performed affinity chromatography of brain extracts on a column of GST:MALS-2 fusion protein and attempted coimmunoprecipitation of erbB4 with MALS from brain extracts. Under a variety of conditions, we were unable to detect association of MALS and erbB4 by these methods (data not shown). This lack of binding is likely attributable to the fact that MALS prefers C-terminal peptides containing glutamate at the −3 position (Fig. 9) but that erbB4 has asparagine at this position. On the other hand, numerous proteins in the PSD, including NMDA receptors and certain K+ channels (Sheng, 1996; Kornau et al., 1997), contain more precisely the C-terminal consensus E-T/S-R/X-V/I/L that determines optimal binding to MALS.

Although we propose a role for MALS in regulating NMDA receptor sorting, it is uncertain how MALS proteins themselves dock to synaptic membranes. The prototypical synaptic PDZ protein PSD-95 is targeted to cell membranes through N-terminal palmitoylation (Topinka and Bredt, 1998). MALS proteins, however, lack N-terminal cysteines or other consensus sequences for lipid modification. It therefore seems more likely that MALS proteins bind to integral or peripheral membrane proteins of the PSD. Although MALS proteins coimmunoprecipitate with PSD-95, we could not detect direct interaction between MALS and PSD-95 and do not favor PSD-95 as a direct anchor for MALS at the PSD. Other likely candidates for targeting MALS to the PSD are the mammalian homologs of LIN-2 (CASK) (Hata et al., 1996) and LIN-10 (Mint/X11) (Borg et al., 1996; Okamoto and Südhof, 1997). Mutations of lin-2 and lin-10 in C. elegans disrupt basolateral targeting of LET-23 (Simske et al., 1996; Kaech et al., 1998), suggesting a possible role for these proteins in targeting of LIN-7. Indeed, very recent studies demonstrate that LIN-7 directly binds to LIN-2, which itself directly associates with LIN-10 (Kaech et al., 1998). This work shows the conserved sequence just N terminal to the PDZ domain of LIN-7 mediates binding to LIN-2 (Kaech et al., 1998). This ternary complex has also been isolated from mammalian brain such that CASK (LIN-2) binds to both Mint-1 (LIN-10) and the Velis (vertebrate homologs of LIN-7), which are apparently identical to the MALS described here (Butz et al., 1998). This ternary complex of CASK/Mint-1/Velis (MALS) is proposed to occur primarily at presynaptic terminals in association with neurexin (Butz et al., 1998). It is not yet known, however, whether this complex might also occur at the PSD. Future anatomical and biochemical studies are needed to address this issue.

Figure 10. The PDZ domain of MALS-2 binds peptides terminating in E-T/S-R/X-V/I/L. Normalized amino acid abundance of the final four residues from 21 independent MALS-2 binding peptides (black bars) is compared with codon frequency in the original library (white bars).
Our finding that MALS is already expressed in brain at E13, an early point of neurogenesis, fits with the developmental function of LIN-7 in vulval development. By analogy, we suspect that MALS proteins may help localize receptors that are important for synaptogenesis. Although mechanisms for synaptic development in brain are unknown, postsynaptic differentiation of the neuromuscular junction requires the activity of a muscle-specific receptor tyrosine kinase, MuSK (DeChiara et al., 1996; Glass et al., 1996). The functional equivalent to MuSK in brain has not yet been identified, but several families of receptor tyrosine kinases occur in developing brain. The largest family of such molecules comprises the ephrin receptors (Flanagan and Vanderhaeghen, 1998). Recent studies have shown that many of the ephrin family receptors, which terminate in V-X-V, are synaptically clustered through interactions with class II PDZ domain-containing proteins (Torres et al., 1998). Although the PDZ domain of MALS is unlikely to interact specifically with ephrin receptors, it will be important to determine whether MALS proteins mediate synaptic localization of other neuronal receptor tyrosine kinases.

Whereas MALS expression is first detectable in developing brain, highest expression levels are found in the adult, suggesting important roles for MALS protein in brain function. Indeed, many processes that are important for brain development remain active in the adult brain to mediate neuronal plasticity necessary for learning and memory. Through interactions with NMDA receptors and other synaptic proteins, MALS may regulate aspects of synaptic plasticity in adult brain. To decisively determine the role of MALS proteins in synaptic development and physiology, it will be important to delete the function of the MALS by knock-out and dominant negative approaches.

REFERENCES


